La Jolla Pharmaceutical Co. (NASDAQ:LJPC)’s share price was down 3.2% during mid-day trading on Thursday . The stock traded as low as $17.94 and last traded at $17.97, with a volume of 84,635 shares trading hands. The stock had previously closed at $18.57.

Several equities analysts have recently issued reports on LJPC shares. Lake Street Capital started coverage on shares of La Jolla Pharmaceutical in a research note on Tuesday, May 24th. They set a “buy” rating and a $25.00 price target for the company. Jefferies Group reaffirmed a “buy” rating on shares of La Jolla Pharmaceutical in a research note on Wednesday, June 8th. Zacks Investment Research downgraded shares of La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Wednesday, June 15th. Finally, SunTrust Banks Inc. started coverage on shares of La Jolla Pharmaceutical in a research note on Wednesday, June 22nd. They set a “buy” rating and a $30.00 price target for the company. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $39.50.

The stock’s market capitalization is $328.02 million. The firm has a 50 day moving average of $16.75 and a 200-day moving average of $17.54.

La Jolla Pharmaceutical (NASDAQ:LJPC) last issued its quarterly earnings data on Friday, May 6th. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.74) by $0.22. On average, equities analysts anticipate that La Jolla Pharmaceutical Co. will post ($3.99) EPS for the current year.

A hedge fund recently raised its stake in La Jolla Pharmaceutical stock. P.A.W. Capital Corp increased its position in La Jolla Pharmaceutical Co. (NASDAQ:LJPC) by 5.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 50,400 shares of the biopharmaceutical company’s stock after buying an additional 2,400 shares during the period. La Jolla Pharmaceutical comprises approximately 1.5% of P.A.W. Capital Corp’s holdings, making the stock its 28th largest position. P.A.W. Capital Corp owned approximately 0.28% of La Jolla Pharmaceutical worth $1,361,000 at the end of the most recent reporting period.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.